Prodrug strategy for enhanced therapy of central nervous system disease.

2021 ◽  
Author(s):  
Xue Xia ◽  
Yang Zhou ◽  
Huile Gao

Central nervous system (CNS) disease is one of the most notorious arch-criminals of human health across the world. Considerable efforts have been devoted to promote the development of CNS drugs...

2016 ◽  
Vol 65 (35) ◽  
pp. 930-933 ◽  
Author(s):  
Anita D. Sircar ◽  
Francisca Abanyie ◽  
Dean Blumberg ◽  
Peter Chin-Hong ◽  
Katrina S. Coulter ◽  
...  

2020 ◽  
Vol 60 (1) ◽  
pp. 291-309 ◽  
Author(s):  
Jesse A. Stokum ◽  
Volodymyr Gerzanich ◽  
Kevin N. Sheth ◽  
W. Taylor Kimberly ◽  
J. Marc Simard

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.


2021 ◽  
Vol 432 ◽  
pp. 213751
Author(s):  
Ke Chen ◽  
Si Sun ◽  
Junying Wang ◽  
Xiao-Dong Zhang

2019 ◽  
Vol 59 (5) ◽  
pp. E33-E37
Author(s):  
Stefano C. Previtali ◽  
Marina Scarlato ◽  
Paolo Vezzulli ◽  
Alessandra Ruggieri ◽  
Daniele Velardo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document